Bile acid metabolism and hepatocellular carcinoma: mechanisms of drug resistance and intervention strategies
Precision Clinical Medicine · 28.06.2025 · 8 (3)
DOI: 10.1093/pcmedi/pbaf020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Precision Clinical Medicine, online erschienen am 20.08.2025. Verfasst von Yan Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Naval Medical University, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the predominant malignant liver tumor, characterized by high morbidity, mortality, and rapid progression, and it ranks among the leading causes of cancer-related fatalities worldwide. Its treatment is facing the severe challenge of resistance to targeted drugs and immunotherapy. Bile acids (BAs) are products of cholesterol metabolism, that not only regulate lipid digestion and absorption, but also influence the development of HCC by modulating inflammation and metabolism. Dysregulation of BA metabolism is closely linked to resistance against targeted therapies and immunotherapies. BAs reduce the efficacy of targeted drugs by influencing enzymes involved in drug metabolism and drug efflux transporters, moreover, BAs also lead to immunotherapeutic resistance by regulating the formation of the immunosuppressive tumor microenvironment. Therefore, regulating BA metabolism has the potential to overcome drug resistance of targeted therapy and immunotherapy, which could be a promising treatment strategy. This review not only summarizes the roles of BA metabolism in HCC development and drug resistance, but also further explores the rationality and necessity of targeting BAs to enhance the survival of HCC patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China.
- The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai 200438, China.
- Clinical Cancer Institute Center for Translational Medicine, Naval Medical University, Shanghai 200433, China.
- Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092, China.
Förderung
- National Natural Science Foundation of China
- Naval Medical University
- China Postdoctoral Science Foundation
Zitieren
APA
Lu, Y., Feng, X., Wang, Z., Zou, M., Xu, Z., Liu, Q., Chen, W., Ding, J., & Liu, H. (2025). Bile acid metabolism and hepatocellular carcinoma: mechanisms of drug resistance and intervention strategies. Precision Clinical Medicine, 8(3). https://doi.org/10.1093/pcmedi/pbaf020
Vancouver
Lu Y, Feng X, Wang Z, Zou M, Xu Z, Liu Q, et al. Bile acid metabolism and hepatocellular carcinoma: mechanisms of drug resistance and intervention strategies. Precision Clinical Medicine. 2025;8(3). doi:10.1093/pcmedi/pbaf020
BibTeX
@article{Lu2025,
author = {Lu, Yan and Feng, Xiaochen and Wang, Zhijie and Zou, Minghao and Xu, Zheqi and Liu, Qianjia and Chen, Wenjin and Ding, Jin and Liu, Hui},
title = {Bile acid metabolism and hepatocellular carcinoma: mechanisms of drug resistance and intervention strategies},
journal = {Precision Clinical Medicine},
year = {2025},
volume = {8},
number = {3},
doi = {10.1093/pcmedi/pbaf020}
}
EUVIMED